10-K: Spruce Biosciences Faces Going Concern Doubts Despite Pipeline Progress

Spruce Biosciences reports significant net losses and raises substantial doubt about its ability to continue as a going concern despite advancements in its clinical development programs.

Summary

• Spruce Biosciences, a biopharmaceutical company, has reported a net loss of $53.0 million for the year ended December 31, 2024, and faces substantial doubt about its ability to continue as a going concern.
• The company's operations have focused on raising capital, protecting intellectual property, and developing product candidates like tralesinidase alfa and tildacerfont.
• Spruce Biosciences anticipates increasing losses as it continues clinical development and seeks regulatory approvals for its product candidates.
• As of December 31, 2024, the company had cash and cash equivalents of $38.8 million and an accumulated deficit of $250.3 million.
• The company is pursuing regulatory approval for TA-ERT for MPS IIIB, with a BLA submission expected in the first half of 2026.
• Spruce Biosciences is also investigating tildacerfont for major depressive disorder through a partnership with HMNC Holding GmbH, with topline results anticipated in the first half of 2026.
• The company has entered into collaboration and license agreements with Kaken Pharmaceutical Co. Ltd. and HBM Alpha Therapeutics, Inc. for tildacerfont and SPR202, respectively.
• Spruce Biosciences relies on third-party contract manufacturing organizations (CMOs) for the production of its product candidates.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• Spruce Biosciences is subject to extensive government regulations and compliance obligations, which are costly and time-consuming.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with significant losses and going concern doubts, tempered slightly by ongoing development efforts and strategic partnerships. The overall tone is negative due to the financial instability.

Positives

• The FDA confirmed that HS-NRE is deemed to be a biomarker reasonably likely to predict clinical benefit and could serve as a basis for accelerated approval for TA-ERT.
• Spruce Biosciences has a strategic partnership with HMNC to investigate tildacerfont for major depressive disorder.
• The company has entered into a Collaboration and License Agreement with HBM Alpha Therapeutics, Inc. for SPR202.
• The company intends to build a highly specialized commercial organization to support the commercialization of TA-ERT, if approved, in the United States.

Negatives

• Spruce Biosciences has a limited operating history and has incurred significant net losses since its inception.
• The company does not currently have sufficient working capital to fund its planned operations for the next twelve months, and substantial doubt exists as to its ability to continue as a going concern.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company relies completely on third parties to manufacture its preclinical and clinical drug supplies.
• The company is highly dependent on its key personnel, and if it is not successful in attracting and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.

Risks

• The company's clinical trials may fail to adequately demonstrate the safety and efficacy of its product candidates.
• The market opportunities for tralesinidase alfa, tildacerfont, and its other current and future product candidates may be smaller than the company believes they are.
• Coverage and reimbursement may be limited or unavailable in certain market segments for tralesinidase alfa, tildacerfont, and its other current and future product candidates.
• The company depends on intellectual property licensed from others, the termination of which could result in the loss of significant rights.
• The company may fail to meet all applicable requirements of the Nasdaq Capital Market, and Nasdaq may determine to delist its common stock.
• Unfavorable U.S. and global economic and geopolitical conditions could adversely affect the company's business, financial condition, or results of operations.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future and will require additional capital to fund its operations.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapid technological advancement, significant competition, and an emphasis on proprietary products. The company faces potential competition from many different sources, including major and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies, compounding pharmacies, and public and private research institutions.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• A thorough comparison would require specific financial metrics and operational data from comparable companies, which are not included in the document.
• Without this information, it is difficult to assess whether Spruce Biosciences' performance is in line with industry benchmarks.

Legal Proceedings

• In January 2025, Neurocrine Biosciences, Inc. filed suit in the United States District Court for the District of Delaware against the company, seeking to invalidate one of its patents.
• Neurocrine has also initiated administrative proceedings against other Spruce patents in the U.S. Patent Office and both judicial and administrative proceedings against Spruce patents in other jurisdictions.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may face uncertainty due to the company's financial instability.
• Patients may benefit from the development of new therapies, but the availability of these therapies is uncertain.

Next Steps

• The company intends to submit the BLA for TA-ERT for the treatment of MPSIIIB in the first half of 2026.
• The company will continue to pursue clinical development of tildacerfont in MDD.
• The company will advance pre-clinical and clinical development of SPR202 in CAH and SPR204 in PBH.

Key Dates

Keywords

Tralesinidase alfa, Tildacerfont, SPR202, SPR204, MPS IIIB, Congenital Adrenal Hyperplasia, Post-Bariatric Hypoglycemia, Clinical trials, Regulatory approval, Biopharmaceutical